Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Agomelatine
Servier Laboratories Ltd
N06AX22
Agomelatine
25mg
Tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04030400; GTIN: 5017476201102
1382_06.02.indd 1 05/10/2017 11:33 1382_06.02.indd 2 05/10/2017 11:33 1382_06.02.indd 3 05/10/2017 11:33 1382_06.02.indd 4 05/10/2017 11:33 Read the complete document
OBJECT 1 VALDOXAN Summary of Product Characteristics Updated 05-Oct-2017 | Servier Laboratories Limited 1. Name of the medicinal product Valdoxan 25 mg film-coated tablets 2. Qualitative and quantitative composition Each film-coated tablet contains 25 mg of agomelatine. Excipient with known effect: each tablet contains 61.84 mg lactose (as monohydrate) For the full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablet [tablet]. Orange-yellow, oblong, 9.5 mm long, 5.1 mm wide film-coated tablet with blue imprint of company logo on one side. 4. Clinical particulars 4.1 Therapeutic indications Treatment of major depressive episodes. Valdoxan is indicated in adults. 4.2 Posology and method of administration Posology The recommended dose is 25 mg once daily taken orally at bedtime. After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to 50 mg once daily, i.e. two 25 mg tablets, taken together at bedtime. Decision of dose increase has to be balanced with a higher risk of transaminases elevation. Any dose increase to 50 mg should be made on an individual patient benefit/risk basis and with strict respect of LFT monitoring. Liver function tests should be performed in all patients before starting treatment. Treatment should not be initiated if transaminases exceed 3 X upper limit of normal (see sections 4.3 and 4.4). During treatment transaminases should be monitored periodically after around three weeks, six weeks (end of acute phase), twelve weeks and twenty four weeks (end of maintenance phase) and thereafter when clinically indicated (see also section 4.4). Treatment should be discontinued if transaminases exceed 3 X upper limit of normal (see sections 4.3 and 4.4). When increasing the dosage, liver function tests should again be performed at the same frequency as when initiating treatment. _Treatment duration_ Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free of symptoms. _Switching t Read the complete document